U.S. Hospital Consumables Market - Growth Overview and Predictions on Size, Share and Trend Through 2025

The U.S. hospital consumables market size is anticipated to reach USD 53.24 billion by 2025, according to a new report by Grand View Research, Inc., experiencing a CAGR of 5.6% during the forecast period. Rising number of surgeries and prevalence of chronic diseases, coupled with expanding geriatric population in the U.S., is promoting the growth of the market.

Geriatric population in the U.S. accounts for a significant share in the overall population of the country. As per a report in 2018 by World Bank, the global population aged 60 years and above was 15.4% of the total population in 2017 in comparison with 12.9% in 2010. Aging makes a person more susceptible to cardiovascular, urological, and neurological diseases, among others. People suffering from these conditions often require surgical interventions. Thus, increasing elderly population is projected to provide an upthrust to the U.S. market.

Based on product, the segments reviewed in the report include medical gloves, medical gauze, disposable syringes, catheters, non-woven disposable products, glucometer strips, IV solutions, and general procedure trays. The non-woven medical disposables segment represented over 29.0% of the overall revenue in 2017. Non-woven disposables are either made from natural fibers, such as cotton and linen, or synthetic fibers such as polypropylene, polytetrafluoroethylene, and polyester. These fabrics protect patients and medical professionals from hospital-acquired infections (HAIs).

General procedure trays are poised to be the most promising product segment during the forecast period. These trays consist of specific tools and instruments used in surgical and diagnostic procedures related to cardiovascular, orthopedics, ophthalmic, and dental procedures, among others. Procedure kits can effectively reduce waste generation in hospitals. Moreover, custom kits can also reduce time required for specific surgeries, leading to a greater number of surgeries being performed in lesser time.

The U.S. hospital consumables market consists of a large number of players manufacturing several products. Some of the players operating in this space are McKesson Medical-Surgical Inc.; Medline Industries, Inc.; B. Braun Melsungen A.G.; Terumo Medical Corporation; Owens and Minor; Smith And Nephew, Inc.; Cardinal Health; and 3M.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/us-hospital-consumables-market

Further Key Findings From the Report Suggest:

• Non-woven disposable products are likely to hold the largest revenue share in the U.S. hospital consumables market throughout the forecast horizon
• General procedure trays are expected to register a CAGR of 10.2% during the same period
• The catheters segment is estimated to command over 17.0% of the overall revenue by 2025.

Liver Cancer Diagnostic Market Analysis and In-Depth Research On Market Dynamics, Trends, Emerging Growth Factors and Forecasts to 2025

The global liver cancer diagnostics market size is expected to reach USD 15.4 billion by 2025, according to a new report by Grand View Research, Inc. The market is projected to expand at a CAGR of 8.1% over the estimated time period. Rise in disease incidence coupled with growing demand for novel diagnosis products are thrusting the growth of the market. Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer in adults. It is among the common causes of death in people with liver cirrhosis and the third-leading cause of cancer deaths across the globe. Poor survival rate and lack of therapies has made this disease a crucial health issue worldwide.

Government and some global health organizations are undertaking initiatives to raise awareness regarding liver cancer through various campaigns. These programs aim to create awareness about signs, symptoms, and complications associated with carcinomas. High costs associated with cancer treatments compared to other diseases have led to increasingly rigid treatment guidelines for expensive drugs and diagnostic tests across various markets. For instance, the Affordable Care Act, designed to improve quality of healthcare and reduce the cost associated with it. This act covers reimbursement for cancer diagnosis and treatment up to a certain extent. Governments in other countries are also taking efforts to overcome challenges, such as cost and access to cancer care.

Such efforts and insurance policies that cover cost of diagnosis and treatment of carcinomas are supporting market growth. Newer techniques developed for hepatocellular carcinoma render both liver transplant, as well as surgical resection, more effective and safer. Several etiological factors of HCC such as hepatitis infection and cirrhosis are modifiable and thus present a strong prospect to reduce disease mortality by preventive strategies. Key players and medical institutions are focusing on the development of advanced tests for HCC diagnosis. These factors along with high unmet needs are expected to propel the growth of liver cancer diagnostics market through the forecast period.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/liver-cancer-diagnostic-market

Further key findings from the study suggest:

• Increasing awareness about liver cancer across the globe is expected to be the major factor driving the market growth
• Laboratory tests emerged as the largest segment owing to increased demand for effective diagnostic tests for HCC
• Oncofetal and Glucoprotein antigens accounted for the largest share in biomarkers segment
• North America led the global liver cancer diagnostic market in 2017 and will maintain the dominance in future on account of rising awareness about early diagnosis and demand for novel diagnostic tests in the region
• Illumina, Inc.; Qiagen; F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; and Thermo Fisher Scientific are some of the leading industry participants

Epigenetics Drugs & Diagnostic Technologies Market Worth USD 22.05 Billion By 2025

The global epigenetics drugs and diagnostic technologies market size is expected to reach USD 22.05 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a 19.7% CAGR during the forecast period. Rising incidence of cancer with epigenetic modification base is projected to drive the market growth.

Diagnostic firms are focused on developing new treatments such as antibodies specific for detection of epigenetic modifications and advanced kits for effective detection of biomarkers. It is likely to encourage pharmaceutical firms to partner for development of new advanced treatments which will further accelerate the market growth.

Presence of a large number of products under clinical trials and their projected commercialization is likely to boost the market. For instance, Eli Lilly’s Ramucirumab have been approved by the U.S. Food and Drug Administration (FDA) to be used in combination with Folfiri for the treatment of metastatic colorectal cancer.

Introduction of technologically advanced products in this space is mostly focused on detection of methylation markers associated with cancer development. For example, Epigenomics introduced Epi proLung BL Reflex Assay which helps in lung cancer diagnosis by determining methylation of SHOX2 biomarker gene.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/epigenetics-drugs-and-diagnostic-technologies-market

Further key findings from the report suggest:

• Reagents is expected to account for the largest market share of over USD 7,058.4 million by 2025 owing to increasing R&D in epigenetics. The kits segment is expected to be in more demand over the forecast period with at CAGR of 20.0% due to need for rapid and accurate detection techniques
• DNA methylation held the major market share of the technology segment in terms of revenue over 47.1% in 2017 owing to rising adoption coupled with development of technological advanced products such as Methylation Sensitive PCR (MSP)
• DNMT inhibitors was the largest segment in 2017 due to the factors such as wide availability of these inhibitors and generics in most regions
• Oncology was the largest revenue generating segment owing to the factors such as growing prevalence of cancer and strong product pipeline
• North America was observed to be the major region for epigenetics market accounting for over 39.3% market share due to high prevalence of cancer, increasing R&D funding, collaborations among big pharmaceutical companies for development of improved treatments, and patient awareness
• Asia Pacific is projected to showcase lucrative CAGR of 22.1% owing to a high number of cancer, diabetes, and other chronic disorders with parallel unmet medical needs
• Major players operating in the epigenetics drugs and diagnostic technologies market include Zymo research; CellCentric Ltd; Thermo Fisher Scientific;Illumina; Abcam; Eisai Co. Ltd; Diagenode; Merck; Syndax Pharmaceuticals, Inc.; Qiagen; Chroma Therapeutics Ltd; Novartis International AG; Oncolys Biopharma Inc.; Sigma-Aldrich Corporation; and Valirx Plc. Widespread R&D activities and clinical studies are expected to boost the market growth over the forecast period.

Marijuana Drying & Curing Equipment Market Worth USD 157.1 Million By 2025

The global marijuana drying and curing equipment market size is expected to reach USD 157.1 million by 2025, according to a new report by Grand View Research, Inc., registering a 10.4% CAGR during the forecast period. Increasing number of countries legalizing cannabis cultivation and consumption, growing cultivation capacity, rising cannabis preference by patients suffering from cancer pain, arthritis, and epilepsy, as well as for other relevant medical conditions are some of the factors driving demand for marijuana drying and curing equipment.

Stringent quality standards for cultivation and curing of medical marijuana is anticipated to boost demand for high quality and potent marijuana produced through organic methods due to their usage in treatment of various medical conditions. These newly developed machines help avoid contamination, prevent moisture variations, preserve active ingredients, and maintain optimum external conditions, all of which were difficult to maintain by traditional methods. Thus, higher product quality obtained through these equipment is expected to drive the market.

The number of weed cultivators has increased at a rapid rate with a rise in the number of countries legalizing marijuana. Globally, North America was the largest contributor in terms of number of marijuana cultivators in 2017. This has had a positive impact on demand for marijuana drying and curing equipment, as consumer demand shifts to high quality and potent products.

U.S. dominated this market in 2017, with a 55.0% revenue share, and is expected to maintain its dominance through 2025. This is attributed due to rapid legalization of cannabis in an increasing number of states in the country and growing consumption of medical cannabis for chronic pain, arthritis, cancer, and epilepsy. U.S. is anticipated to witness incremental opportunity of USD 17.6 million between 2018 and 2025, owing to potential legalization of cannabis in other states. Germany is expected to witness the second-highest incremental opportunity of USD 11.7 million between 2020 and 2025 as the country is expected to start distributing licenses for weed cultivation in early 2019. This, in turn, is expected to drive demand for marijuana drying and curing equipment over the forecast period.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/marijuana-drying-curing-equipment-market

Further key findings from the report suggest:

• U.S. dominated the global market in 2017, owing to rising number of states legalizing the cultivation, sale, and consumption of marijuana; the incremental opportunity in the country is expected to be USD 17.6 million between 2018 to 2025
• Germany is anticipated to be the fastest growing market with a CAGR of 5.9 % between 2020 and 2025. The country is expected to start distributing licenses for weed cultivation in early 2019
• Some of the key market players in the market are Cann Systems, LLC; Darwin Chambers; Conviron; Autocure; Yofumo Technologies, Inc.; DHydra Technologies; EnWave Corporation; HARTER GmbH; and PROTEIN SOLUTIONS GROUP, LLC.

Why Growing Your Own pharmaceutical grade lactose Is the Best Resolution for 2019

The global pharmaceutical grade lactose market size is expected to reach USD 254.8 million by 2025 at a 4.6% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Rising inclination toward preventive healthcare across the globe is estimated to boost product use over the forecast period.

Increasing investments by local and foreign players in the pharmaceutical manufacturing sector, especially in developing economies such as India and Brazil, is expected to have a positive influence on industry growth. Furthermore, increased access to medication through generic drug production and development of innovative treatments for chronic diseases has resulted in the growth of the drug manufacturing industry, thereby propelling product demand.

Raw material prices and operational and transportation costs are key factors that define final product price. Intense competition in the industry is expected to put pressure on prices, resulting in a decline in product price. In addition, higher product prices have lowered buyers’ interest, owing to availability of substitutes, which is also expected to hamper growth.

Stringent government regulations associated with the use of pharmaceutical grade lactose are expected present a barrier to entry of new players in the market. In addition, high initial cost and operation cost associated with production machinery is expected to further discourage new entrants, thereby lowering their threat.

The industry is characterized by presence of major industry players focussing on research and development activities in order to reduce overall manufacturing cost by using innovative techniques. Participants have been adopting competitive strategies such as setting up new manufacturing facilities to magnify their regional presence.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/pharmaceutical-grade-lactose-market

Further key findings from the report suggest:

• Europe dominated the industry in 2017 in terms of product consumption and was valued at USD 74.7 million owing to increasing product adoption and well-established pharmaceutical industry
• Asia Pacific accounted for 33.4% of the total revenue in 2017, owing to government initiatives to provide affordable prescription drugs and highest number of FDA-approved pharmaceutical lactose products in the region
• The industry is characterized by increasing integration across the value chain, with participants looking to expand their footprint and strengthen their position in both manufacturing and distribution

Single Lead ECG Equipment Market 2019: Growth Factor, Manufacturers, Market Dynamics, Shipments and Revenue

The global single lead ECG equipment market size is estimated to reach USD 487.59 million by 2025, progressing at a 4.72% CAGR during the forecast period, according to a new report by Grand View Research, Inc.

Emergence of smartphone and mobile-based cardiac monitoring devices has been revolutionized the market in the past few years. Medical device manufacturers continue to invest in development of these products in order to overcome pitfalls associated with conventional means of cardiac assessment. This is, consequently, fostering the growth of the market.

An Indian company Agatsa Software Pvt. Ltd. introduced credit-card-sized ECG monitors, “Sanket”, which measures ECG in 15 seconds and displays results that can be sent to anyone across the globe via email, social media platforms, or SMS. Such advancements in ECG monitoring devices are anticipated to shape the future of the market over the forecast period.

On the other hand, government bodies are undertaking initiatives for improvement in treatment of cardiac disorders in order to satisfy escalating need for inexpensive and portable devices for regular cardiac monitoring as a preventive step. This, in turn, is expected to positively influence the growth of the market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/single-lead-ecg-equipment-market

Further key findings from the study suggest:

• Widening base of patients suffering from cardiovascular diseases is expected to augment the single lead portable ECG equipment market
• The demand for portable ECGs serving home/ambulatory services for risk identification for occurrence of cardiac diseases is projected to grow at a faster pace in the near future
• The growth of the home/ambulatory segment is supported by continuous improvement in software/algorithms for regular cardiac monitoring
• Availability of products that can carry out continuous and real time wireless ambulatory patient monitoring is contributing to the growth of the market
• North America accounted for the largest market share in 2017, owing to well-established healthcare system coupled with rise in prevalence of cardiovascular diseases in the region
• Presence of several nascent and established participants in the region further drives the R&D and novel product launches in the U.S.
• Asia Pacific is likely to witness the fastest growth during the forecast period owing to rising patient awareness pertaining to portable technologies as well as increasing healthcare expenditure in developing economies
• Rise in patient as well as physician awareness and inclination towards medical technology and cloud-based software programs are expected to encourage substantial growth in the region